R
Remo H.M. Furtado
Researcher at University of São Paulo
Publications - 68
Citations - 5110
Remo H.M. Furtado is an academic researcher from University of São Paulo. The author has contributed to research in topics: Medicine & Myocardial infarction. The author has an hindex of 14, co-authored 49 publications receiving 3121 citations. Previous affiliations of Remo H.M. Furtado include Brigham and Women's Hospital & Albert Einstein Hospital.
Papers
More filters
Journal ArticleDOI
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.
Remo H.M. Furtado,Otávio Berwanger,Henrique Andrade Rodrigues da Fonseca,Thiago Domingos Corrêa,Leonardo José Rolim Ferraz,Maura G Lapa,Fernando G. Zampieri,Viviane C Veiga,Luciano Cesar Pontes Azevedo,Regis Goulart Rosa,Renato D. Lopes,Alvaro Avezum,Airton Leonardo de Oliveira Manoel,Felipe Maia de Toledo Piza,Priscilla de Aquino Martins,Thiago Lisboa,Adriano José Pereira,Guilherme B Olivato,Vicente C.S. Dantas,Eveline P. Milan,Otavio Gebara,Roberto Bleuel Amazonas,Monalisa Fernanda Bocchi de Oliveira,Ronaldo V P Soares,Diogo D.F. Moia,Luciana P.A. Piano,Kleber Castilho,Roberta G.R.A.P. Momesso,Guilherme Schettino,Luiz Vicente Rizzo,Ary Serpa Neto,Ary Serpa Neto,Flávia Ribeiro Machado,Alexandre Biasi Cavalcanti +33 more
TL;DR: The findings do not support the routine use of azithromycin in combination with hydroxychloroquine in patients with severe COVID-19 and suggest that standard of care treatment alone did not improve clinical outcomes.
Journal ArticleDOI
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
Thomas A Zelniker,Thomas A Zelniker,Marc P. Bonaca,Marc P. Bonaca,Remo H.M. Furtado,Remo H.M. Furtado,Ofri Mosenzon,Julia F Kuder,Sabina A. Murphy,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P.H. Wilding,Andrzej Budaj,Róbert Gábor Kiss,Francisco Padilla,Ingrid Gause-Nilsson,Anna Maria Langkilde,Itamar Raz,Marc S. Sabatine,Stephen D. Wiviott +20 more
TL;DR: Dapagliflozin decreased the incidence of reported episodes of AF/AFL adverse events in high-risk patients with type 2 diabetes mellitus and was consistent regardless of the patient’s previous history of AF, atherosclerotic cardiovascular disease, or HF.
Journal ArticleDOI
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Remo H.M. Furtado,Remo H.M. Furtado,Marc P. Bonaca,Itamar Raz,Thomas A Zelniker,Ofri Mosenzon,Avivit Cahn,Julia F Kuder,Sabina A. Murphy,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P.H. Wilding,Christian T. Ruff,Jose C. Nicolau,Ingrid Gause-Nilsson,Martin Fredriksson,Anna Maria Langkilde,Marc S. Sabatine,Stephen D. Wiviott +19 more
TL;DR: In this article, the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus and a history of atherosclerotic cardiogenesis was reduced by using Sodium glucose transporter-2 inhibitors.
Journal ArticleDOI
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
Mikhail Kosiborod,Mikhail Kosiborod,Russell Esterline,Remo H.M. Furtado,Jan Oscarsson,Samvel B. Gasparyan,Gary G. Koch,Felipe Martinez,Omar Mukhtar,Subodh Verma,Subodh Verma,Vijay K. Chopra,Joan Buenconsejo,Anna Maria Langkilde,Philip Ambery,Fengming Tang,Kensey Gosch,Sheryl L. Windsor,Emily E Akin,Ronaldo V P Soares,Diogo D.F. Moia,Matthew Aboudara,Conrado R. Hoffmann Filho,Audes D. M. Feitosa,Alberto Fonseca,Vishnu Garla,Robert Gordon,Ali Javaheri,Cristiano P Jaeger,Paulo Leães,Michael E. Nassif,Michael Pursley,Fabio Serra Silveira,Weimar Kunz Sebba Barroso,José Roberto Lazcano Soto,Lilia Nigro Maia,Otavio Berwanger +36 more
TL;DR: The DARE-19 trial as discussed by the authors was a randomized, double-blind, placebo-controlled trial of patients hospitalised with COVID-19 and with at least one cardiometabolic risk factor (i.e., hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease).
Journal ArticleDOI
Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021
Jose C. Nicolau,Gilson Soares Feitosa Filho,João Luiz Fernandes Petriz,Remo H.M. Furtado,Dalton Bertolim Précoma,Walmor Lemke,Renato D. Lopes,Ari Timerman,José A Marin Neto,Luiz Bezerra Neto,Bruno Ferraz de Oliveira Gomes,Eduardo Cavalcanti Lapa Santos,Leopoldo S. Piegas,Alexandre de Matos Soeiro,Alexandre Jorge de Andrade Negri,Andre Franci,Brivaldo Markman Filho,Bruno Mendonça Baccaro,Carlos Eduardo Lucena Montenegro,Carlos E. Rochitte,Carlos J.D.G. Barbosa,Cláudio Marcelo Bittencourt das Virgens,Edson Stefanini,Euler Roberto Fernandes Manenti,Felipe Gallego Lima,Francisco das Chagas Monteiro Júnior,Harry Correa Filho,Henrique Patrus Mundim Pena,Ibraim Pinto,João Luiz de Alencar Araripe Falcão,Joberto Pinheiro Sena,José Maria Peixoto,Juliana Ascenção de Souza,Leonardo Sara da Silva,Lilia Nigro Maia,Louis Nakayama Ohe,Luciano Moreira Baracioli,Luís Alberto Oliveira Dallan,Luís Augusto Palma Dallan,Luiz Alberto Mattos,Luiz Carlos Bodanese,Luiz Eduardo Fonteles Ritt,Manoel Fernandes Canesin,Marcelo Bueno da Silva Rivas,Marcelo Franken,Marcos José Gomes Magalhães,Mucio Tavares de Oliveira Junior,Nivaldo Menezes Filgueiras Filho,Oscar Pereira Dutra,Otávio Rizzi Coelho,Paulo Leães,Paulo Roberto Ferreira Rossi,Paulo R. Soares,Pedro Alves Lemos Neto,Pedro Silvio Farsky,Rafael Rebêlo C. Cavalcanti,Renato Jorge Alves,Renato A. K. Kalil,Roberto Esporcatte,Roberto Luiz Marino,Roberto R. Giraldez,Romeu Sergio Meneghelo,Ronaldo de Souza Leão Lima,Rui Fernando Ramos,Sandra Nívea dos Reis Saraiva Falcão,Talia Dalcoquio,Viviana de Mello Guzzo Lemke,William Azem Chalela,Wilson Mathias Junior +68 more
TL;DR: Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instavel and Infarto Agudo do Miocardio sem Supradesnivel do Segmento ST.